Every year, almost half of people with tuberculosis (TB) are not diagnosed or notified to health systems – resulting in millions of preventable deaths.

To reduce TB deaths by 90% by 2030, we need simple, rapid tests that work for everyone, everywhere.

FIND IS WORKING WITH PARTNERS TO

ENABLE UNIVERSAL ACCESS TO TB DIAGNOSTICS
with tools that work in community and primary healthcare settings and use samples that are easy and convenient for all people to provide.

- Multi-pathogen point-of-care molecular tests
- Swab and urine-based testing
- Person-centred delivery models
- Integrated testing

PRESEVER DRUGS & TREATMENT REGIMENS
by testing response to critical drugs, directing patients to effective treatments, and safeguarding against antimicrobial resistance.

- New drug-resistance tests
- Next-generation sequencing (NGS)
- Capacity building and infrastructure upgrades
- Diagnostic network optimization (DNO)

INTERRUPT DISEASE TRANSMISSION
and drive the development and uptake of tests and digital tools that promote community screening and early detection of TB in all its forms.

- Imaging and computer-assisted detection (CAD)
- Simpler tools for TB infection
- AI and digital diagnostic support
- Active case-finding strategies

END TUBERCULOSIS

MAKING RELIABLE TESTS A REALITY FOR ALL TO
ENSURING EVERYONE WHO NEEDS A TB TEST CAN GET ONE

Taking advantage of new and existing technologies, FIND is working to develop solutions that increase the availability of diagnostic tools for TB and improve access to them. Our focus is on meeting the needs of key groups and populations (such as children and people living with HIV), and the expansion of diagnostic testing to make it available everywhere that people seek care.

SPOTLIGHTS

TB TESTS TO IMPROVE DIAGNOSIS IN CHILDREN
New molecular stool-based tests have the power to transform diagnostic testing for TB in children. With product development and evaluation supported by FIND, WHO formally recommended their use in 2021. Nine countries have since adopted stool-based testing, with FIND providing technical assistance to others looking to take advantage of this important new test. In India, molecular testing has been enabled for nearly 95,000 children with suspected TB between 2014 and 2018 with 89% of those diagnosed linked to treatment.

NEW TOOLS TO IMPROVE COMMUNITY-BASED TESTING
In a study of over 4,000 people, the TB-CAPT consortium demonstrated that placing battery-operated molecular diagnostic tests in primary healthcare centres in Tanzania and Mozambique improved case detection rates and demonstrated that a same-day test-and-treat strategy is feasible for TB. The approach was implemented in a low-resource setting and was shown to be feasible, practical and widely acceptable to patients and healthcare workers alike.

A JOINT EFFORT FOR THE ELIMINATION OF TB IN INDIA
Launched in 2018, this project is the largest private-sector health engagement initiative for TB ever to be carried out in India. As an implementing partner, FIND helped notify over 200,000 people with TB in 3 years and increase treatment adherence to over 80%. The second phase of work provides preventative TB treatment to household contacts of people with pulmonary TB in four Indian states. As of August 2023, over 300,000 contacts have been screened, with more than 200,000 people starting preventative treatment and more than 8 out of 10 people completing the course.

INFORMING POLICIES TO HARNESS NEW TECHNOLOGIES
Targeted next-generation sequencing (tNGS) can cut the detection and profiling of drug-resistant TB from months to days. Advances in artificial intelligence (AI) can expand TB screening services by supporting chest X-ray reading to address the global shortage of radiologists. As policy-makers welcome new technologies, FIND is on-track to become a certified WHO prequalification assessor, supporting with clinical validation, as well as roll-out and implementation of approved new tools.

“The 2030 goal of ending TB remains ambitious, but the roadmap to get there is clear and diagnostic testing is a critical element to stop transmission and save lives.”

MORTEN RUHWALD, DIRECTOR OF TB, FIND

OUR IMPACT IN NUMBERS (2010–2022)

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>New diagnostic tools</td>
<td>27</td>
</tr>
<tr>
<td>Countries with optimized TB diagnostic networks</td>
<td>17</td>
</tr>
<tr>
<td>WHO recommendations supported</td>
<td>6</td>
</tr>
<tr>
<td>People tested</td>
<td>4.2M+</td>
</tr>
<tr>
<td>Drug-resistant TB cases notified in India</td>
<td>200,000</td>
</tr>
</tbody>
</table>

WITH THANKS TO OUR KEY DONORS SUPPORTING OUR TB WORK

[Image for acknowledgments]